Pharmacokinetic-Pharmacodynamic Modeling of Remimazolam Versus Propofol in Patients Undergoing Colonoscopy
Background: To ensure the patient's comfort and the success of the procedure, sedation is necessary during a colonoscopy. Despite its widespread use, propofol can cause dose-dependent respiratory depression and hypotension, despite its fast onset and recovery. There is new hope for an alternative with a perhaps better safety profile: rimmazole, an ultra-short-acting benzodiazepine. In this study, the objective was to examine the PK-PD profiles of propofol and remimazolam in individuals who were due to have colonoscopies. Methods: This prospective comparison study involved 40 patients designated for elective colonoscopy at a tertiary care facility. Patients were randomly assigned to two groups: Group R (n = 20) was administered remimazolam, while Group P (n = 20) was administered propofol for procedural sedation. Sequential blood samples were obtained to ascertain plasma drug concentrations, and sedation depth was evaluated utilizing the Modified Observer’s Assessment of Alertness/Sedation (MOAA/S) scale. Pharmacokinetic parameters, including clearance, volume of distribution, and half-life, were computed. The primary outcomes included onset time, recovery time, hemodynamic stability, and adverse events. Pharmacokinetic-pharmacodynamic modeling was conducted utilizing nonlinear mixed-effects modeling. Results: Remimazolam had a markedly reduced context-sensitive half-life (0.75 ± 0.15 h) in contrast to propofol (1.8 ± 0.4 h, p < 0.001). The mean clearance of the remimazolam group (1.15 ± 0.25 L/min) exceeded that of the propofol group (0.85 ± 0.20 L/min, p < 0.01). The duration to achieve sufficient sedation (MOAA/S ≤ 3) was similar between groups (2.5 ± 0.5 min vs 2.0 ± 0.4 min, p > 0.05). Recovery time was significantly shorter in the remimazolam group (8.5 ± 2.0 min) compared to the propofol group (12.0 ± 3.0 min, p < 0.01). Hemodynamic stability was more effectively preserved with remimazolam, with fewer instances of hypotension (10% versus 30%) and respiratory depression (5% versus 25%) in comparison to propofol. Pharmacokinetic-pharmacodynamic modeling revealed a consistent concentration-effect relationship for both agents, with remimazolam exhibiting a broader therapeutic window. Conclusion: Remimazolam is an effective sedative that has a better PK-PD profile than propofol, which means it improves hemodynamic stability, has a faster recovery time, and is safer overall. As a substitute for procedural sedation during colonoscopies, it is both safe and effective.